Loading...
A novel CIP2A and BCL-XL clinical diagnostic toolkit to predict disease progression and treatment-free remission in Chronic Myeloid Leukaemia
Basabrain, Ammar A. Austin, Gemma M. Holcroft, Alison K. Apperley, Jane F. Clark, Richard E. Varadarajan, Shankar Lucas, Claire
Basabrain, Ammar A.
Austin, Gemma M.
Holcroft, Alison K.
Apperley, Jane F.
Clark, Richard E.
Varadarajan, Shankar
Lucas, Claire
Advisors
Editors
Other Contributors
EPub Date
Publication Date
2026-03-25
Submitted Date
Collections
Files
Loading...
Published version
Adobe PDF, 1.95 MB
Other Titles
Abstract
Biomarkers that predict disease progression and treatment-free remission (TFR) would be of significant clinical value in chronic myeloid leukaemia (CML). We have previously shown that CIP2A levels at diagnosis can identify patients at increased risk of progression. One mechanism by which CIP2A acts is through upregulation of the anti-apoptotic gene BCL-XL. In this study, we evaluated BCL-XL mRNA expression as a diagnostic biomarker using samples from the SPIRIT2 and DESTINY clinical trials. In SPIRIT2, which compared imatinib and dasatinib as first-line therapies, high BCL-XL expression was associated with treatment failure, poor early molecular response, and lower rates of MR2 and MR3 achievement in patients treated with imatinib. In the DESTINY trial, which assessed treatment de-escalation and discontinuation, BCL-XL expression was significantly higher in patients who experienced molecular relapse compared to those achieving sustained TFR. Notably, increases in BCL-XL were detectable 6 to 8 months prior to molecular relapse, suggesting it may serve as an early biomarker of unsuccessful TFR. We now propose a clinical diagnostic toolkit combining CIP2A and BCL-XL biomarkers to stratify CML patients by the risk of disease progression and likelihood of achieving successful TFR.
Citation
Basabrain, A. A., Austin, G. M., Holcroft, A. K., Apperley, J. F., Clark, R. E., Varadarajan, S., & Lucas, C. M. (2026). A novel CIP2A and BCL-XL clinical diagnostic toolkit to predict disease progression and treatment-free remission in Chronic Myeloid Leukaemia. International Journal of Molecular Sciences, 27(7), 2991. https://doi.org/10.3390/ijms27072991
Publisher
MDPI
Journal
International Journal of Molecular Sciences
Research Unit
PubMed ID
PubMed Central ID
Type
Article
Language
en
Description
© 2026 by the authors. Licensee MDPI, Basel, Switzerland.
Series/Report no.
ISSN
1661-6596
EISSN
1422-0067
ISBN
ISMN
Gov't Doc
Test Link
Sponsors
This project was funded by The Deanship of Scientific Research (DSR) at King Abdulaziz University, Jeddah, under grant no. IPP: 1598-142-2025. The authors, therefore, acknowledge with thanks DSR for technical and financial support. Dr. Lucas was also supported by University of Chester QR funding for this project (RO1 IOM00052).